Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia

Exclusion Criteria

• •1. Failure to perform screening or baseline examinations
• •2. Hospitalization within 8 weeks before screening, or change of antipsychotic medication or dose within 2 months prior to screening
• •3. Subjects who have participated in another clinical trial with an experimental medication within the past 2 months.
• •4. Patient has had cognitive battery similar to those used in this study within the last 12 months
• •5. Subjects with other Diagnostic and Statistical Manual (DSM-V) Axis I or Axis II primary diagnoses
• •6. Diagnosis of alcohol or substance abuse or dependence within the past 3 months,
• •7. Significant suicide risk as determined by the Columbia Suicide Severity Rating Scale (C-SSRS)
• •8. Subjects who plan to begin a new course of cognitive remediation therapy, or have been receiving cognitive remediation therapy for less than one year. .
• •9. History of myocardial infarction, unstable angina, uncontrolled hypotension or hypertension within 3 months before screening.
• •10. Clinically significant abnormality on screening ECG
• •11. Alanine transaminase (ALT) or aspartate transaminase (AST) \> 2.5 times the upper limit of normal (ULN)
• •12. History of stroke, brain tumor, head trauma with loss of consciousness, or other clinically significant neurological condition within 12 months before screening
• •13. Subjects with other uncontrolled medical conditions, in the opinion of the investigator
• •14. Polypharmacy with two or more antipsychotic drugs or mood stabilizers
• •15. Use of benzodiazepines
• •16. Individuals with kidney dysfunction will not be enrolled, as dysfunctional kidneys may have difficulty clearing the magnesium from the body
• •17. Individuals who are currently taking magnesium supplements